Tyramine reactions
Some foods and drinks contain tyramine. When its breakdown is strongly reduced, tyramine can raise norepinephrine activity and may trigger a dangerous blood-pressure reaction.
Plain-language reference
MAOI Risks Guide
A reader-focused way to separate the three major interaction hazards: tyramine-related blood-pressure reactions, serotonergic toxicity, and switching or washout errors.
Educational information only. Concerning symptoms after a possible interaction call for urgent evaluation.
At a glance
The three interaction hazards
MAOIs affect enzymes that normally help break down certain naturally occurring and medication-related chemicals. The result is not one single risk; it is a set of interaction patterns that can overlap.
Serotonergic toxicity
Combining medicines or substances that increase serotonin signaling can produce a rapidly worsening toxic state, especially when several effects stack together.
Washout mistakes
An interaction can occur when a medicine is started, stopped, or changed before its effects have cleared sufficiently. Timing is part of the exposure picture.
Exposure map
The label “MAOI” covers different situations
Irreversible, nonselective MAOIs are often the clearest example of broad interaction concern because they affect both MAO-A and MAO-B. Examples include phenelzine, tranylcypromine, and isocarboxazid. A medicine’s name alone does not tell the whole story: formulation, dose, selectivity, and local availability all matter.
Transdermal selegiline has dose-dependent considerations. Selective MAO-B inhibitors such as rasagiline are used in another clinical context but can still matter when combined with other agents. Reversible MAO-A medicines, where available, have their own interaction context. Nonpsychiatric exposures matter too: linezolid is an antibiotic with MAOI activity, and intravenous methylene blue can have potent MAO-A inhibitory activity.
The plain-language MAOI interaction overview provides the broader context for this guide, while the medication-specific label remains the relevant source for a particular product and situation.
Hazard one
Tyramine, explained without the jargon
Tyramine is a naturally occurring compound found at higher levels in some aged, fermented, cured, spoiled, or improperly stored foods. Ordinarily, monoamine oxidase in the digestive tract and liver helps limit how much tyramine reaches the bloodstream. Strong MAO inhibition can reduce that protection.
That matters because tyramine can prompt release of norepinephrine, a chemical involved in blood-vessel tone and blood pressure. The historical term “cheese reaction” is too narrow: aged cheeses are one example, but cured meats, fermented soy products, some yeast extracts, tap beers, and other aged or fermented products can also be relevant depending on the medicine and product information.
The National Library of Medicine’s overview of monoamine oxidase inhibitors describes the connection between MAO inhibition, tyramine, and hypertensive reactions.
Hazard two
When drug effects stack on serotonin
Serotonergic toxicity is the second major pattern. It is associated with combinations that increase serotonin signaling, particularly when an MAOI is paired with another serotonergic substance or when multiple serotonergic agents overlap during a medication change.
Examples that may be implicated include many antidepressants, certain migraine medicines, tramadol, meperidine, dextromethorphan in some cough products, and some anti-nausea medicines. Supplements and nonprescription substances can matter as well; St. John’s wort and products marketed around serotonin are examples worth recognizing as possible interaction categories.
Serotonin syndrome is a recognized toxic state; the Wikipedia overview of serotonin syndrome summarizes its characteristic combination of mental-status, autonomic, and neuromuscular findings.
Hazard three
Why switching and washouts deserve their own category
The word “washout” describes the interval considered when moving between medicines with potentially overlapping effects. It is discussed with MAOIs because an effect may outlast the last dose, particularly with irreversible inhibitors that require the body to make more enzyme.
Starting
An interaction framework has to consider medicines already present, including longer-acting products and recent nonprescription or supplement use.
Changing
Different medicines clear at different rates. Product-specific instructions and medical context determine why a particular interval may be discussed.
Stopping
Stopping an MAOI does not always end every interaction concern immediately. The mechanism and formulation influence the relevant timeline.
For a focused explanation of the vocabulary used around transitions, see the switching and washouts guide. This page does not provide an individual medication schedule or a substitute for product-specific professional guidance.
Urgent signs
Symptoms that should not be minimized
A severe headache, chest pain, marked agitation or confusion, high fever, rigid muscles, pronounced tremor, seizures, fainting, or a rapidly worsening condition can be concerning after a possible MAOI interaction. These signs can have more than one cause, but they are not symptoms to sort out through online information alone.
The U.S. Food and Drug Administration notes that methylene blue can cause serious central nervous system reactions in people taking serotonergic psychiatric medicines, illustrating why hospital and procedural exposures belong in an interaction conversation.
Common questions
A few useful distinctions
These answers keep the focus on recognizing interaction categories, not directing an individual treatment decision.
Are all MAOIs associated with the same interaction concerns?
No. Interaction concerns vary by medicine, dose, formulation, selectivity, and how long the medicine continues to affect monoamine oxidase. The categories in this guide are a framework for understanding why a specific product label matters.
Can an antibiotic or procedural medicine have MAOI activity?
Yes. Linezolid and intravenous methylene blue are notable examples outside psychiatric prescribing. This is why a complete medication and exposure history can matter across care settings.
Why do food lists differ between products?
Food guidance reflects the type of MAO inhibition, dose, formulation, labeling, and local product information. A generalized list is useful for recognizing tyramine-rich categories, but it is not a personal dietary instruction.
Where can I find the scope of this independent resource?
Our approach to clear, evidence-first information explains the purpose and limits of MAOI Interaction Guide. It does not replace urgent care, a medicine label, or individualized professional guidance.
Safety note
Concerning symptoms require urgent evaluation.
This guide is designed to make MAOI interaction language easier to recognize. It cannot assess a current reaction or determine the safety of a specific medicine, food, supplement, or switch.